Skip to main content
Premium Trial:

Request an Annual Quote

Nimbus Receives Additional Funding to Further Develop Protein Targets for Drug Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nimbus Discovery today announced an extension of its seed round of funding, which will be used to advance drug programs based on its in silco discovery platform.

The funding comes from Bill Gates and Richard Freisner, co-founder of chemical simulation software firm Schrödinger and a professor of chemistry at Columbia University. Atlas Venture, the founding investor in Nimbus, also was a participant.

Nimbus did not disclose the amount of the investment.

The funds will be used to advance the company's lead programs in diffuse large B-cell lymphoma, inflammatory disorders, and metabolic disease, Nimbus said. It is targeting proteins crucial in disease progression, including IRAK4 and ACC.

Nimbus said that its pipeline stems from a partnership forged in 2010 with Schrödinger, which provided Nimbus access to its WaterMap software and related technologies, as well as rights to key targets.

The WaterMap software calculates the locations and thermodynamic properties of water molecules that solvate the binding sites of a protein, allowing for the calculation of relative binding affinities of congeneric compounds that bind to the protein.

Nimbus, headquartered in Cambridge, Mass., also has exclusive use of customized software packages developed by Schrödinger for the targets, access to computational chemists at Schrödinger, and unlimited use of cloud computing resources.

Schrödinger, in return, has a material stake in Nimbus and will receive milestone payments.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.